Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database

Table 4

All-cause mortality (excluding suicide), cardiac mortality, and sudden cardiac death: current antipsychotic use versus nonuser psychiatric.

Outcome	Treatment	Number of events	PY	Incidence rate per 1000 PY; (95% CI)	Fully adjusted RR (aRR); (95% CI)
All-cause mortality	Nonuser psychiatric	7765	307,276	25.3 (24.7–25.8)	Reference
	Amisulpride	503	5220	96.4 (88.1–105.2)	1.51 (1.37–1.66)^‡
	Chlorpromazine	1553	28,550	54.4 (51.7–57.2)	1.59 (1.49–1.69)^‡
	Haloperidol	5552	21,045	263.8 (256.9–270.9)	2.33 (2.12–2.56)^‡
	Olanzapine	1305	34,985	37.3 (35.3–39.4)	1.04 (0.93–1.17)
	Perphenazine	260	8507	30.6 (27.0–34.5)	1.30 (0.91–1.85)
	Quetiapine	1887	17,216	109.6 (104.7–114.7)	1.42 (1.34–1.50)^‡
	Risperidone	3600	33,917	106.1 (102.7–109.7)	1.64 (1.56–1.72)^‡
Cardiac mortality	Nonuser psychiatric	1289	200,988	6.4 (6.1–6.8)	Reference
	Amisulpride	98	3936	24.9 (20.2–30.3)	2.50 (1.76–3.57 )^‡
	Chlorpromazine	161	15,220	10.6 (9.0–12.3)	1.70 (1.11–2.58) )^†
	Haloperidol	522	11,546	45.2 (41.4–49.3)	2.10 (1.59–2.77) ^‡
	Olanzapine	206	26,765	7.7 (6.7–8.8)	1.53 (1.12– 2.09) ^‡
	Perphenazine	22	3232	6.8 (4.3–10.3)	0 (NC)
	Quetiapine	344	15,183	22.7 (20.3–25.2)	1.79 (1.38–2.33)^‡
	Risperidone	543	25,024	21.7 (19.9–23.6)	1.87 (1.44 –2.41)^‡
Sudden cardiac death (secondary definition)	Nonuser psychiatric	98	23,873	4.1 (3.3–5.0)	Reference
	Amisulpride	15	674	22.3 (12.5–36.7)	0 (NC)
	Chlorpromazine	10	1297	7.7 (3.7–14.2)	0 (NC)
	Haloperidol	47	1236	38.0 (28.0–50.6)	4.33 (3.03–6.17)^‡
	Olanzapine	10	3454	2.9 (1.4–5.3)	0 (NC)
	Perphenazine	0	221	0.0 (0.0–16.7)	0 (NC)
	Quetiapine	46	3407	13.5 (9.9–18.0)	1.51 (1.04–2.19)^†
	Risperidone	17	2187	7.8 (4.5–12.4)	0 (NC)

^∗𝑃<0.10; ^†𝑃<0.05; ^‡𝑃<0.01.
Abbreviations: aRR: adjusted relative risk; CI: confidence interval; NC: not calculated; PY: person-years.